Перговерис Drug photo

The description is actual on 20.07.2016

  • Latin name: Pergoveris
  • ATH code: G03GA30
  • Active ingredient: Follitropin alpha (Follitropin alfa), lutropin alpha (Lutropin alfa)
  • Producer: Merck Serono S.A. (Switzerland)


In 1 bottle — follitropin an alpha 150 ME, a lutropina an alpha 75 ME.

Sucrose, hydrophosphate sodium dihydrate, methionine, phosphoric acid, dihydrophosphate sodium monohydrate, polysorbate, sodium hydroxide as auxiliary components.

Release form

Lyophilisate in bottles for solution preparation, is applied solvent.

Pharmacological action


Pharmacodynamics and pharmacokinetics


The combined drug which contains the recombinant follicle-stimulating hormone of the person and recombinant luteinizing hormone received by a genetically engineered method.
FSG stimulates a folliculogenesis, and LG regulates maturing of a follicle and an ovulation. Besides, it supports normal function of a yellow body that is necessary for approach of pregnancy and its development. Action of LG consists also in development of androgens which in an effect are transformed to estrogen without which conditions for pregnancy approach are not created, growth of an endometria and maturing of a yellow body is broken.

Drug is shown at the gipogonadtropny hypogonadism at women which is followed by deficit of LG and FSG. Pergoveris at EKO, IKSI, EKO is applied + by IKSI. Advantages of additional purpose of a lutropin the alpha is proved (r-LGch) at insufficient efficiency of stimulation by one r-FSGch. Addition raises it sensitivity of ovaries to r-FSGch.


Lutropin an alpha at p / to introduction is distributed in bodies, bioavailability about 60%. In an organism is defined during 5 h. The pharmacokinetics at single introduction same, as well as at repeated, cumulation at the same time is minimum. At simultaneous use with follitropin the alpha of interaction is not noted.

Bioavailability of follitropin an alpha at p / to introduction of 70%. At repeated uses triple cumulation of drug is noted. Css is reached in 3–4 days.

Indications to use

Programs of reproductive technologies if:

  • the suboptimal answer (maturing from 4 to 6 follicles) at earlier carried out stimulation was noted by pure FSG;
  • the age of the woman is more senior than 35 years and earlier the suboptimal response to stimulation was noted;
  • stimulation of growth of follicles at the expressed deficit of LG and FSG without use of VRT.


  • uterine bleedings of not clear genesis;
  • cancer of an ovary, mammary gland, uterus;
  • tumors of a hypothalamus or hypophysis;
  • volume cysts of ovaries;
  • uterus tumors which are incompatible with pregnancy;
  • congenital anomalies of generative organs which are incompatible with pregnancy;
  • primary ovarian insufficiency;
  • pregnancy;
  • feeding by a breast;
  • hypersensitivity.

Side effects

Often met side reactions:

  • headache;
  • drowsiness;
  • cysts of ovaries;
  • abdominal pain, abdominal colic;
  • syndrome of hyper stimulation of ovaries of different severity;
  • nausea, vomiting;
  • frustration of a chair, meteorism;
  • reactions in the place of an injection (bruise, pain, a swelling, reddening).

Seldom met side reactions:

  • thromboembolism (at a severe form of a syndrome of hyper stimulation of ovaries);
  • exacerbation of bronchial asthma at patients with asthma;
  • system allergic reactions (urticaria, rash, generalized hypostasis, difficulty of breath, fever, face edema, arthralgia, anaphylaxis);
  • ovary apoplexy;
  • polycarpous pregnancy;
  • extrauterine pregnancy.

Pergoveris, application instruction (Way and dosage)

Treatment is carried out only under control of the doctor. Drug is intended for hypodermic introduction. Lyophilisate is dissolved solvent and at once I use all dose.

Stimulation of growth and maturing of follicles at the expressed deficit of LG and FSG

The course of treatment is begun in any day of a cycle. An initial dose — 1 bottle a day. Duration of a course is individual, depends on the follicle growth/size which are defined by ultrasonography monitoring, and values of estrogen in blood. Within one cycle of stimulation increase in its duration up to 5 weeks is possible.

In need of increase in a dose r-FSGch, it is increased in 7-14 days, by only 37,5-75 ME follitropins an alpha. At achievement of the optimum answer in 24-48 h 5000-10000 ME HGch is entered. Sexual contact or intrauterine insemination is recommended in day of introduction of HGch or next day.

At the excessive response to stimulation treatment is stopped and introduction of HGch is postponed. The course of therapy is renewed in the following cycle, but use lower dose r-FSGch.

Stimulation by Pergoveris at the suboptimal answer in earlier carried out VRT programs

The treatment mode usually begins with 300 ME usual r-FSGch, once a day 5-7 days. From the seventh day of stimulation simple r-FSGch replace with 2 bottles Pergoveris. There are also alternative schemes which are developed by the doctor, proceeding from specific features of the patient and results of the previous stimulations. The daily dose r-FSGch should not be more than 450 ME.

Treatment is carried out to a necessary level of development of a follicle which is defined by ultrasonic research and on concentration of estrogen in blood. At achievement of this level enter HGch necessary for final maturing of follicles and carry out extraction of an oocyte. Abstain from introduction of HGch at significant increase in ovaries, stop treatment. It renews from the following cycle and lower dose of drug is applied.


Cases of overdose are not registered. The syndrome of hyper stimulation of ovaries is possible.


About incompatibility with other drugs there are no data. It is impossible to mix drug Pergoveris with others in one syringe, the exception makes follitropin an alpha.

Terms of sale

It is released according to the recipe of the doctor.

Storage conditions

Temperature of storage is up to 25 °C.

Period of validity

3 years.


Coincidence on the ATH code of the 4th level:


About Pergoveris

Long-term supervision and researches confirmed that patients with the suboptimal or poor response to simulation in the past for prevention of this complication need to appoint LG-soderzhashchiye drugs, and pure FSG in the raised dose.

For this reason at such patients Pergoveris who prevents the weakened reaction to stimulation by gonadotrophins is applied, reduces the frequency of the suboptimal answer and improves results of EKO. Contained in drug rlgch (lutropin an alpha) improves quality of oocytes and the received embryos, increases readiness of an endometria for implantation and increases probability of successful conception. Many data on efficiency and safety of this drug which has a number of advantages are saved up.
According to patients it appointed stimulation by this drug if the weakened reaction to gonadotrophins was registered in last programs of reproductive technologies. Responses are contradictory:

  • "… Stimulated with Pergoveris, on him 30 follicles from which took 25 grew. Drug really strong";
  • "… There was a stimulation by Pergoveris, only 2 follicles ripened";
  • "… I had 2 protocols, both on it. Gave rise to twin!".

Some, proceeding from the experience, consider what at stimulation of follicles by Menopur ripens less, but quality is better than them.


  • Pergoveris lyophilisate for Preeg. solution for injections 150ME + 75ME No. 1 a bottle + rastvoritelmerk Serrano S.p.a.
to show still


  • Pergoveris por.dlya prig.rastvor 150ME fl. + r-@ 1 ml No. 1 Serono's (Switzerland) Laboratory
Section: Gynecologic
in more detail

Education: Graduated from Sverdlovsk medical school (1968 - 1971) as "Paramedic". Graduated from the Donetsk medical institute (1975 - 1981) as "An epidemiologist, a hygienist". Passed postgraduate study in the Central scientific research institute of epidemiology Moscow (1986 - 1989). An academic degree – the candidate of medical sciences (degree is awarded in 1989, protection – the Central scientific research institute of epidemiology Moscow). Numerous advanced training courses are studied in epidemiology and infectious diseases.

Experience: Work as the manager of department of disinfection and sterilization of 1981 - 1992. Work as the manager of department of especially dangerous infections of 1992 - 2010. Teaching activity at Medical institute 2010 - 2013.

PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before medicine use Pergoveris surely consult with the attending physician.